Moreover, the colony-forming activity showed that PKM2 (Y105F) and SHP-1 (D61A) decreased the anti-proliferation effect of sorafenib, suggesting that PKM2 and SHP-1 could be therapeutic determinants of sorafenib in HCC cells (Figure 5F). The gene discussed is PTPN6; the disease is hepatocellular carcinoma.